- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02210689
A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study treatment period will be 1 day. Subject participation is 22-30 days. Expected study duration is 10 to 12 months. The study will enroll in up to 30 clinical sites.
Test Product: One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
Reference Product: One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
Placebo Control: One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
Dose and Mode A single applicator of investigational product cream will be administered of Administration once intravaginally at any time of the day. The subject participation is 22-30 days (drug administration for 1 day).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Republica Dominicana
-
Santo Domingo, Republica Dominicana, Dominican Republic
- Akesis investigator site 3
-
Santo Domingo, Republica Dominicana, Dominican Republic
- Akesis investigator site 4
-
-
-
-
-
Ponce, Puerto Rico
- Akesis Investigator site 2
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
- Akesis Investigator site 5
-
-
California
-
La Mesa, California, United States
- Akesis Investigator site 12
-
San Diego, California, United States
- Akesis investigator site 6
-
-
Florida
-
Boynton Beach, Florida, United States
- Akesis Investigator site 1
-
North Miami, Florida, United States
- Akesis investigator site 14
-
Sanford, Florida, United States, 32771
- Akesis investigator site 17
-
Sunrise, Florida, United States
- Akesis investigator site 8
-
West Palm Beach, Florida, United States
- Akesis Investigator site 10
-
-
Georgia
-
Roswell, Georgia, United States
- Akesis Investigator site 9
-
-
Louisiana
-
Metairie, Louisiana, United States
- Akesis Investigator site 15
-
-
New Jersey
-
Lawrenceville, New Jersey, United States
- Akesis investigator site 16
-
-
New York
-
Port Jefferson, New York, United States
- Akesis investigator site 11
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Akesis investigator site 13
-
-
Tennessee
-
Jackson, Tennessee, United States
- Akesis Investigator site 7
-
-
Texas
-
Houston, Texas, United States, 77011
- Akesis investigator site 18
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits and must provide the written informed consent prior to any study related procedure being performed.
- Healthy non-pregnant female aged ≥ 18 years with no known medical conditions that, in the investigator's opinion, may interfere with study participation or may interfere with the evaluation of bacterial vaginosis.
Female subjects of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test must be willing to use an acceptable form of birth control during the study from the day of the first dose administration to the Visit 2 Test-of-cure. For the purpose of this study the following are considered acceptable methods of birth control:
- Oral or injectable contraceptives
- Contraceptive patches
- Depo-Provera® (stabilized for at least 3 months); Implanon™ (contraceptive implant), or abstinence with one of the above-listed methods of birth control should the Subject become sexually active.
- A sterile sexual partner is NOT considered an adequate form of birth control.
- Willing to refrain from sexual intercourse on study days 1-7 and for 48 hours prior to Visit 2 Test-of-cure.
- Willing to refrain from using any vaginal product (e.g., spermicide, tampon, douche, diaphragm, or condom) other than study product, on study Days 1-7, for 48 hours prior to the first dose of study product, and for 48 hours prior to Visit 2 Test-of-cure.
Diagnosis of bacterial vaginosis, defined as the presence of all of the following:
- Clinical diagnosis of bacterial vaginosis (e.g., thin, homogenous vaginal discharge associated with minimal or absent pruritus or inflammation AND
- Saline wet mount of vaginal discharge demonstrating the proportion of clue cell to be ≥ 20% of the total epithelial cells AND
- Vaginal pH > 4.5, using pH paper that measures from 4.0-6.0 AND
- Positive "whiff test" after addition of a drop of 10% KOH to vaginal discharge)
- Gram stain Nugent score ≥ 4 on first day of dosing (study day 1) (per Table 1 below).
- Table 1: Nugent Scoring System (0-10) for Gram-stained Vaginal Smears (a)
- Score (b) Lactobacillus morphotypes Gardnerella and Bacteroides spp. morphotypes Curved gram-variable rods
- 0 4+ 0 0
- 1 3+ 1+ 1+ or 2+
- 2 2+ 2+ 3+ or 4+
- 3 1+ 3+
- 4 0 4+
Source: Nugent, R. P., M. A. Krohn, and S. L. Hillier. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J. Clin. Microbial. 1991; 29: 297-301.
- Morphotypes are scored as the average number seen per oil immersion field. Note that less weight is given to curved gram-variable rods. Total score = lactobacilli + G. vaginalis and Bacteroides spp/ + curved rods.
- 0, No morphotypes present; 1, <1 morphotype present; 2, 1 to 4 morphotypes present; 3, 5 to 30 morphotypes present; 4, 30 or more morphotypes present.
Exclusion Criteria:
- Female subjects who are pregnant, nursing or planning to become pregnant during study participation.
- Menstruating when diagnosis of bacterial vaginosis is determined at Baseline visit.
- Primary or secondary immunodeficiency.
- Severe liver disease.
- History of regional enteritis, ulcerative colitis, or a history of "antibiotic-associated" colitis.
- Evidence of any vulvovaginitis other than bacterial vaginosis. (e.g., candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Herpes simplex).
- Subjects with visible signs of HPV infection, i.e. visible warts.
- Subject with another vaginal or vulvar condition, which would confound the interpretation of clinical response.
- Subject will be under treatment during the study period for cervical intraepithelial neoplasia (CIN) or cervical carcinoma.
- History of hypersensitivity to clindamycin, lincomycin, or any of the components of the vaginal creams.
- Use within 2 weeks prior to baseline of 1) topical or systemic antibiotics or 2) topical or systemic antifungal.
- Use of spermicides, tampons, douches, diaphragms, condoms within 48 hours of the baseline visit.
- Concurrent use of systemic corticosteroids or systemic antibiotics.
- Unwilling or unable to comply with the protocol requirements.
- Subjects who have participated in an investigational drug study (i.e., subjects have been treated with an investigational drug) within 30 days prior to baseline will be excluded from study participation. Subjects who are participating in non-treatment studies such as observational studies or registry studies can be considered for inclusion.
- Subjects who have been previously enrolled in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: test product
One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
|
|
Active Comparator: reference product
One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
|
|
Placebo Comparator: placebo
One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
|
vehicle used as placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Both a Clinical and a Bacteriological Cure (Nugent Score <4), Evaluated at Visit 2 Test-of-cure (Study Day 22-30).
Time Frame: 22 to 30 days
|
Clinical Cure is defined as resolution of clinical signs and symptoms from entry visit as follows:
A Bacteriological cure is defined as a Nugent score < 4. The system used a 0-4 scale (Nugent Scoring System 0-10 for Gram-Stained Vaginal Smears) for evaluation of vaginal flora, based on the weighted sum of the following 3 bacterial morphotypes scores calculated from slide examination under oil immersion field:
|
22 to 30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: nageshwar r thudi, Ph.D., CCRP, Actavis Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Vaginitis
- Inflammation
- Vaginal Diseases
- Vaginosis, Bacterial
- Vaginal Discharge
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Clindamycin
- Clindamycin palmitate
- Clindamycin phosphate
Other Study ID Numbers
- 13-1052
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BACTERIAL VAGINOSIS
-
CDA Research Group, Inc.TerminatedBacterial Vaginosis (BV)United States
-
Alfasigma S.p.A.ParexelTerminatedBACTERIAL VAGINOSISUnited States
-
Zagazig UniversityRecruitingBacterial Vaginosis | Vaginal | MicrobiologyEgypt
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
University of Alabama at BirminghamWayne State UniversityCompletedRecurrent Bacterial VaginosisUnited States
-
Zagazig UniversityUnknownBacterial Vaginosis TreatmentEgypt
-
Unity Health TorontoCompleted
-
Mount Sinai Hospital, CanadaUnity Health TorontoCompletedPregnant Women Who Test Positive for Bacterial VaginosisCanada
-
Universiti Kebangsaan Malaysia Medical CentreNot yet recruitingBacterial Vaginoses
-
National Institute of Allergy and Infectious Diseases...Completed
Clinical Trials on clindamycin phosphate vaginal cream 2%
-
Skaraborg HospitalCompleted
-
Zagazig UniversityUnknownBacterial Vaginosis TreatmentEgypt
-
Daré Bioscience, Inc.Completed
-
Meir Medical CenterCompletedVulvovaginal Atrophy | Dyspareunia Among Puerperal WomenIsrael
-
Wake Forest UniversityMedicis Pharmaceutical CorporationCompleted
-
Skaraborg HospitalUnknownInfection, BacterialSweden
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedAcne VulgarisUnited States
-
Taro Pharmaceuticals USACompletedAcne VulgarisUnited States
-
Lumara Health, Inc.CompletedVaginitis | VulvovaginitisUnited States, Russian Federation, Puerto Rico, India
-
Texas Tech University Health Sciences CenterCompleted